According to the present invention, peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 9, 23, 25, 30, 60, 63 or 68 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from the group of SEQ ID NOs: 3, 4, 9, 23, 25, 30, 60, 63 and 68. The peptide can include one, two, or several amino acid substitutions or addition so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for treating and/or prophylaxis of tumors, and/or prevention of postoperative recurrence thereof, which comprises any of these peptides. The pharmaceutical agents of this invention include vaccines.根據本發明,包含胺基酸序列SEQ ID NO:3、4、9、23、25、30、60、63或68的胜肽已被證實具有細胞毒性T淋巴細胞(CTL)誘導性。因此,本發明提供一種具有選自SEQ ID NOs:3、4、9、23、25、30、60、63與68之胺基酸序列的胜肽。只要該胜肽保持其細胞毒性T淋巴細胞誘導性,該胜肽便可包括一、二或數個胺基酸取代或加成。此外,本發明提供用以治療和/或預防腫瘤以及/或其術後復發的藥劑,該藥劑包含任何上述的胜肽。本發明之藥劑包括疫苗。
